NIPT – Non-Invasive Prenatal Testing in India | Advanced Fetal Genetic Screening

Yaazh Xenomics offers highly accurate **Non-Invasive Prenatal Testing (NIPT)** in India using state-of-the-art Next-Generation Sequencing (NGS) technology. Our NIPT test analyzes cell-free fetal DNA (cffDNA) circulating in maternal blood to screen for common chromosomal aneuploidies and select microdeletions with exceptional sensitivity and specificity.

What is NIPT (Non-Invasive Prenatal Testing)?

NIPT is a screening test performed as early as 10 weeks of pregnancy. It analyzes fragments of fetal DNA present in the mother’s bloodstream (cell-free fetal DNA) without any risk to the fetus. Unlike invasive procedures such as amniocentesis or CVS, NIPT is completely safe and carries no risk of miscarriage.

Our NIPT Technology & Methodology

Key Features of Yaazh Xenomics NIPT

• Targeted NGS-based approach with deep sequencing coverage
• Analysis of chromosomes 13, 18, 21, X, and Y
• Optional microdeletion screening (22q11.2, 1p36, Angelman/Prader-Willi, Cri-du-chat)
• Fetal fraction estimation with quality control metrics
• Advanced bioinformatics pipeline with proprietary algorithms
• High sensitivity (>99.9% for Trisomy 21) and specificity (>99.9%)

Conditions Screened by Our NIPT Test

Core Aneuploidy Screening

• Trisomy 21 (Down Syndrome)
• Trisomy 18 (Edwards Syndrome)
• Trisomy 13 (Patau Syndrome)
• Sex Chromosome Aneuploidies (Turner, Klinefelter, Triple X, XYY)

Optional Microdeletion Panel

• 22q11.2 Deletion Syndrome (DiGeorge/Velocardiofacial syndrome)
• 1p36 Deletion Syndrome
• Angelman/Prader-Willi Syndrome (15q11–q13)
• Cri-du-chat Syndrome (5p deletion)

NIPT Workflow at Yaazh Xenomics

1. Pre-Test Genetic Counselling – Detailed discussion of test limitations, sensitivity, and clinical implications
2. Maternal Blood Collection – 10 ml peripheral blood in specialized cfDNA tubes (from 10 weeks gestation)
3. Cell-Free DNA Extraction & Library Preparation
4. Targeted Next-Generation Sequencing – Deep sequencing of selected chromosomal regions
5. Advanced Bioinformatics Analysis – Proprietary algorithms for fetal fraction estimation and aneuploidy detection
6. Clinical Reporting & Post-Test Counselling – Clear, easy-to-understand report with genetic counsellor support

Clinical Performance

• Sensitivity for Trisomy 21: >99.9%
• Specificity for Trisomy 21: >99.9%
• Positive Predictive Value significantly higher than traditional serum screening
• Low no-call rate due to robust fetal fraction estimation

Who Should Consider NIPT?

• All pregnant women (as a primary screening test)
• Women with advanced maternal age (≥35 years)
• High-risk pregnancies identified by first-trimester combined screening
• History of previous chromosomal abnormality
• Parental balanced translocation carriers

Advantages of NIPT at Yaazh Xenomics

• Non-invasive – Zero risk to mother or fetus
• Early detection – From 10 weeks of gestation
• Higher accuracy than traditional first and second trimester screening
• Advanced bioinformatics with low false positive rate
• Fast turnaround time (7–14 working days)
• Affordable pricing with transparent packages

Yaazh Xenomics Pvt Ltd
Module No. 103, TICEL BIOPARK Phase – III,
Maruthamalai Road, Coimbatore – 641046, Tamil Nadu, India

Phone: +91 99431 32020 | +91 95002 45454
Email: info@yaazhxenomics.com